SARS-CoV-2 Spike RBD Antibody

R&D Systems, part of Bio-Techne | Catalog # MAB11294

R&D Systems, part of Bio-Techne
Catalog #
Availability
Size / Price
Qty
MAB11294-100
MAB11294-SP
Print Quote
Bulk Order
100% Guarantee

Key Product Details

Species Reactivity

SARS-CoV-2

Applications

Blockade of Receptor-ligand Interaction, Immunocytochemistry, Neutralization

Label

Unconjugated

Antibody Source

Monoclonal Mouse IgG1 Clone # 1049417

View all Spike RBD Antibodies »

Product Specifications

Immunogen

Human embryonic kidney cell, HEK293-derived sars-cov-2 Spike S1 Subunit protein
Val16-Pro681
Accession # YP_009724390.1

Specificity

Detects SARS-CoV-2 Spike RBD in ELISA.

Clonality

Monoclonal

Host

Mouse

Isotype

IgG1

Scientific Data Images for SARS-CoV-2 Spike RBD Antibody

Detection of Spike RBD in Transfected & Wild Type HEK293 Human Embryonic Kidney Cell Line.

Spike RBD was detected in immersion fixed Transfected & absent in Wild Type HEK293 Human Embryonic Kidney Cell Line using Mouse Anti-SARS-CoV-2 Spike RBD Monoclonal Antibody (Catalog # MAB11294) at 8 µg/mL for 3 hours at room temperature. Cells were stained using the NorthernLights™ 557-conjugated Anti-Mouse IgG Secondary Antibody (red; Catalog # NL007) and counterstained with DAPI (blue). Specific staining was localized to cytoplasm. View our protocol for Fluorescent ICC Staining of Cells on Coverslips.

SARS-CoV-2 variant protein (named 20A.EU2) binding to ACE-2-transfected Human Cell Line is Blocked by SARS2-20A.EU2 S1 Antibody.

In a functional flow cytometry test, Recombinant SARS-CoV2 20A.EU2 S1 His-tagged protein (10780-CV) binds to HEK293 human embryonic kidney cell line transfected with recombinant human ACE-2 and eGFP. (A) Binding is completely blocked by 25 µg/mL of Mouse Anti-SARS2-20A.EU2 S1 Antibody (Catalog # MAB11294) but not by (B) Mouse IgG1 Isotype Control (MAB002). Protein binding was detected with Mouse Anti-His APC-conjugated Monoclonal Antibody (IC050A). Staining was performed using our Staining Membrane-associated Proteins protocol.

SARS-CoV-2 Spike RBD ELISA Standard Curve

In a functional ELISA, 20.0 - 200 ng/mL of this antibody will block 50% of the binding of 50 ng/mL Recombinant Human ACE‑2 (933-ZN) to Recombinant SARS-CoV-2 20A.EU2 Spike S1 Subunit His-tag (10780-CV) immobilized at 0.2 ug/mL (100 µL/well).

Applications for SARS-CoV-2 Spike RBD Antibody

Application
Recommended Usage

Blockade of Receptor-ligand Interaction

In a functional flow cytometry test, 25 μg/mL of MsxSARS2-20A.EU2 S1 Antibody (Catalog # MAB11294) will block the binding of Recombinant SARS-CoV2 20A.EU2 S1 Protein (Catalog # 10780-CV) to HEK293 human embryonic kidney cell line transfected with recombinant human ACE-2.

Immunocytochemistry

8-25 µg/mL
Sample: Immersion fixed Transfected & Wild Type HEK293 Human Embryonic Kidney Cell Line

Neutralization

In a functional ELISA, 20.0 - 200 ng/mL of this antibody will block 50% of the binding of 50 ng/mL Recombinant Human ACE‑2 (Catalog # 933-ZN) to Recombinant SARS-CoV-2 20A.EU2 Spike S1 Subunit His-tag (Catalog # 10780-CV) immobilized at 0.2 ug/mL (100 µL/well).
Please Note: Optimal dilutions of this antibody should be experimentally determined.

Formulation, Preparation, and Storage

Purification

Protein A or G purified from hybridoma culture supernatant

Reconstitution

Reconstitute at 0.5 mg/mL in sterile PBS. For liquid material, refer to CoA for concentration.

Reconstitution Buffer Available:
Size / Price
Qty

Formulation

Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.

Shipping

Lyophilized product is shipped at ambient temperature. Liquid small pack size (-SP) is shipped with polar packs. Upon receipt, store immediately at the temperature recommended below.

Stability & Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: Spike RBD

SARS-CoV-2, which causes the global pandemic coronavirus disease 2019 (Covid-19), belongs to a family of viruses known as coronaviruses that are commonly comprised of four structural proteins: Spike protein (S), Envelope protein (E), Membrane protein (M), and Nucleocapsid protein (N) (1). SARS-CoV-2 Spike Protein (S Protein) is a glycoprotein that mediates membrane fusion and viral entry. The S protein is homotrimeric, with each ~180-kDa monomer consisting of two subunits, S1 and S2 (2). In SARS-CoV-2, as with most coronaviruses, proteolytic cleavage of the S protein into the S1 and S2 subunits is required for activation. The S1 subunit is focused on attachment of the protein to the host receptor while the S2 subunit is involved with cell fusion (3-5). The S1 protein of SARS-CoV-2 shares 65% and 22% amino acid (aa) sequence identity with the S1 protein of SARS-CoV-1 and MERS, respectively. The S Protein of the SARS-CoV-2 virus, like the SARS-CoV-1 counterpart, binds Angiotensin-Converting Enzyme 2 (ACE2), but with much higher affinity and faster binding kinetics through the receptor binding domain (RBD) located in the C-terminal region of S1 (6). Based on structural biology studies, the RBD can be oriented either in the up/standing or down/lying state with the up/standing state associated with higher pathogenicity (7). Polyclonal antibodies to the RBD of the SARS-CoV-2 S1 protein have been shown to inhibit interaction with the ACE2 receptor, confirming RBD as an attractive target for vaccinations or antiviral therapy (8). It has been demonstrated that the S Protein can invade host cells through the CD147/EMMPRIN receptor and mediate membrane fusion (9, 10). A SARS-CoV-2 variant (named 20A.EU2) carrying the S1 subunit amino acid (aa) change S477N and D614G emerged presumably in France and becomes the second most common variant in western Europe (11).

References

  1. Wu, F. et al. (2020) Nature 579:265.
  2. Tortorici, M.A. and D. Veesler (2019) Adv. Virus Res. 105:93.
  3. Bosch, B.J. et al. (2003). J. Virol. 77:8801.
  4. Belouzard, S. et al. (2009) Proc. Natl. Acad. Sci. 106:5871.
  5. Millet, J.K. and G.R. Whittaker (2015) Virus Res. 202:120.
  6. Ortega, J.T. et al. (2020) EXCLI J. 19:410.
  7. Yuan, Y. et al. (2017) Nat. Commun. 8:15092.
  8. Tai, W. et al. (2020) Cell. Mol. Immunol. https://doi.org/10.1016/j.it.2020.03.007.
  9. Wang, X. et al. (2020) https://doi.org/10.1038/s41423-020-0424-9.
  10. Wang, K. et al. (2020) bioRxiv https://www.biorxiv.org/content/10.1101/2020.03.14.988345v1.
  11. Hodcroft, E.B. et al. (2020) medRxiv https://doi.org/10.1101/2020.10.25.20219063.

Long Name

Spike Receptor Binding Domain

Entrez Gene IDs

3200426 (HCoV-HKU1); 14254594 (MERS-CoV); 1489668 (SARS-CoV); 43740568 (SARS-CoV-2)

Gene Symbol

S

UniProt

YP_009724390.1

Additional Spike RBD Products

Product Documents for SARS-CoV-2 Spike RBD Antibody

Product Datasheets

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Note: Certificate of Analysis not available for kit components.

Download SDS

Product Specific Notices for SARS-CoV-2 Spike RBD Antibody

For research use only

Privacy and Cookie Policy
Site Map
© Copyright 2024 Bio-Techne. All Rights Reserved.